REGNのPER（株価収益率）は？

Regeneron Pharmaceuticals Inc（REGN）は現在PER 18.14倍で取引されています。

REGNのROE（自己資本利益率）は？

Regeneron Pharmaceuticals IncのROEは1,000,000.00%です。

REGNの配当利回りは？

Regeneron Pharmaceuticals Incの配当利回りは0.49%です。

REGNの品質スコア（Quality Score）は？

当社のAIはREGNの総合財務品質を100点中92点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

REGNは今が買い時ですか？

当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

REGNはどのセクターに属しますか？

Regeneron Pharmaceuticals IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

REGN (NASDAQ) 株価分析 | REGENERON PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-06-30)

REGN AI Analysis Summary

Our AI summary for REGN: Regeneron Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 18.14, ROE of 1,000,000.00%, a dividend yield of 0.49%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

REGN

Regeneron Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 81

USD 759.24

-3.39 (-0.44%) Day Change

Watchlist Portfolio Compare Chart

18.14

P/E

62,647.03

D/E

1,000,000.0%

ROE

1,000,000.0%

ROA

0.49%

Div Yield

5.78

PEG

REGENERON PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 759.24 Price -3.39 (-0.44%) Day Change	NEWS SCORE: 81

REGN, ファンダメンタルスコアはexcellent ( ファンダメンタル = 92) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

92 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

64%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	81
Magic Formula Rank by ROA	707
Magic Formula Rank by ROE	707
Magic Formula Rank by ROIC	805
Price	759.24
PBV / Sector	1,000,000.00 / 44,219.29 GREAT
Earning Per Share	41.86

PE / Sector	18.14 / 19.28
PEG or PE/Growth / Sector	5.78 / 1.23
Average 1M Daily Value	530.04 M
Average 1W Daily Value	769.32 M

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	27.86 / 98.22 GREAT
NPM Average (%) / Sector	31.22 / -1,697.63 GREAT
NPM Change Average (%) / Sector	-5.63 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	1,000,000.00 / 185,260.96
ROA Average (%) / Sector	2,074,632.49 / 36,684.70 GOOD
ROA Change Average (%) / Sector	23,347,876.88 / 422,221.66 GREAT
ROE (%) / Sector	1,000,000.00 / 243,762.23
ROE Average (%) / Sector	2,730,106.42 / 48,758.47
ROE Change Average (%) / Sector	23,678,147.98 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

41%

Dividend (%) / Sector	0.49 / 0.04
Dividend Average (%) / Sector	0.47 / 17.04
Dividend Change Average (%) / Sector	7.32 / -0.19

登録情報

Analyze Date	2026-08-04 08:02:04
Symbol	REGN
Name	REGENERON PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	101.14 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	78,516.57 / 9,645.64

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707

Phone: 914 847 7000

Website: https://www.regeneron.com

Employees: 15,410

Sector: Healthcare >> Biotechnology

Description: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.